The CCAS-scale in hereditary ataxias: helpful on the group level, particularly in SCA3, but limited in individual patients.
Andreas ThiemeJennifer FaberPatricia SulzerKathrin ReetzImis DoganMiriam BarkhoffJanna KraheHeike JacobiJulia-Elisabeth AktoriesMartina MinneropSaskia ElbenRaquel van der VeenJohanna MüllerGiorgi BatsikadzeJürgen KonczakMatthis SynofzikSandra RoeskeDagmar TimmannPublished in: Journal of neurology (2022)
As a group, SCA3 patients performed below the level of SCA6 and FRDA patients, possibly reflecting additional cerebral involvement. Moreover, the application of the CCAS-Scale in its present form results in a high number of false-positive test results, that is identifying controls as patients, reducing its usefulness as a screening tool for CCAS in individual patients.